Relay Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M | $82.7M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | — | — | — | — | $99.9M |
| SG&A Expense | $56.7M | $76.6M | $75.0M | $66.0M | $57.4M | $38.6M |
| Operating Income | $-302.7M | $-372.5M | $-373.0M | $-299.3M | $-364.7M | $-55.8M |
| Operating Margin | -1,971.6% | -3,722.1% | -1,460.1% | -21,670.9% | -12,040.2% | -67.5% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-276.5M | $-337.7M | $-342.0M | $-290.5M | $-363.9M | $-52.4M |
| Net Margin | -1,800.6% | -3,374.7% | -1,338.7% | -21,036.1% | -12,012.9% | -63.4% |
| EPS (Basic) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-5.40 |
| EPS (Diluted) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-5.40 |
| Shares Outstanding (Basic) | 171.6M | 142.9M | 122.6M | 112.2M | 95.1M | 42.6M |
| Shares Outstanding (Diluted) | 171.6M | 142.9M | 122.6M | 112.2M | 95.1M | 42.6M |
| Dividends Per Share | — | — | — | — | — | — |